March 21, 2018 6:32 PM ET

Healthcare Equipment and Supplies

Company Overview of Ekso Bionics Holdings, Inc.

Company Overview

Ekso Bionics Holdings, Inc. designs, develops, and sells exoskeletons for use in the healthcare, industrial, military, and consumer markets in North America, Europe, the Middle East, and Africa. The company operates through Medical Devices, Industrial Sales, and Engineering Services segments. It primarily offers Ekso GT, a bionic suit that provides the ability to stand and walk over ground with a reciprocal gait using a cane, crutches, or a walker to individuals with spinal cord injuries, hemiplegia due to stroke, and lower limb paralysis or weakness. The company’s Ekso device is primarily used in a clinic or rehabilitation setting. It also performs research and development work on human exo...

1414 Harbour Way South

Suite 1201

Richmond, CA 94804

United States

Founded in 2005

89 Employees





Key Executives for Ekso Bionics Holdings, Inc.

Chief Financial Officer
Age: 55
Total Annual Compensation: $242.7K
Chief Operating Officer
Age: 55
Total Annual Compensation: $301.1K
Chief Marketing Officer
Age: 49
Total Annual Compensation: $307.3K
Compensation as of Fiscal Year 2016.

Ekso Bionics Holdings, Inc. Key Developments

Ekso Bionics® to Expand Clinical Trial Sites for Comparative Multicenter WISE Study

Ekso Bionics Holdings, Inc. announced that it will be expanding the first company-sponsored randomized, controlled clinical trial, the WISE (Walking Improvement for SCI with Exoskeletons) study, to TIRR Memorial Herman and Barrow Neurological Institute. Led by Dylan Edwards, Ph.D., P.T., of the Burke Medical Research Institute, the U.S. based-study, which will now be conducted at ten centers, will evaluate improvement in independent gait speeds of patients with spinal cord injuries (SCI) who are receiving rehabilitation with the EksoGT™, the Company’s wearable exoskeleton, compared to standard of care. In addition to the two new participating WISE study sites, the following centers have been initiated: Burke Medical Research Institute, Courage Kenny Rehabilitation Institute, DMC Rehabilitation Institute of Michigan, Gaylord Hospital, Kennedy Krieger Institute, Kessler Foundation, Marianjoy Rehabilitation Hospital, part of Northwestern Medicine and Shirley Ryan AbilityLab. The multicenter WISE study incorporates three randomized clinical arms. Participants in Group 1 will undergo rehabilitation with a combination of the EksoGT™ and overground walking three times a week for 12 weeks. Group 2 will undergo rehabilitation consisting of standard gait training three times a week utilizing a combination of body-weight supported treadmill training and overground training for 12 weeks. Group 3 will be a passive control group; participants will continue with normal daily activities for 12 weeks with no therapy. All groups will be evaluated at baseline, 6 weeks, and 12 weeks. The primary endpoint of the WISE study seeks to demonstrate that a 12-week robotic gait training regimen can lead to a clinically meaningful improvement in independent walking speed. Secondary endpoints from the trial will examine economic factors such as number of physical therapists and staff required during training, the physical burden on physical therapists assisting and supervising during training, and the influence of factors that may modify the gait recovery.

Ekso Bionics Holdings, Inc. Announces Resignation of Russdon Angold as the President of the EksoWorks

Effective January 22, 2018, Russdon Angold resigned as the President of the EksoWorks business unit of Ekso Bionics Holdings, Inc. and from all other positions with the company in connection with a leadership transition in the Company.

Ekso Bionics Holdings, Inc. Provides Sales Guidance for the Fourth Quarter and Full Year Ended December 31, 2017

Ekso Bionics Holdings, Inc. provided sales guidance for the fourth quarter and full year ended December 31, 2017. For the quarter, the company expects to report revenue of over $2.5 million. For the year, total revenue was approximately $7.4 million, compared to $7.7 million in 2016, excluding a one-time recognition of $6.5 million in 2016 of deferred revenue on previously shipped units.

Similar Private Companies By Industry

Company Name Region
.decimal, Inc. United States
20/20 GeneSystems Inc. United States
20/20 Imaging LLC United States
206 Ortho, Inc. United States
21st Century Scientific, Inc. United States

Recent Private Companies Transactions

No transactions available in the past 12 months.

The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
The Advertising Council, Inc. United States
Tax Management Inc United States
John F. Kennedy Center For The Performing Arts United States
NYC2012, Inc. United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Ekso Bionics Holdings, Inc., please visit Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at